Amantadine controlled-release - Adamas Pharmaceuticals

Drug Profile

Amantadine controlled-release - Adamas Pharmaceuticals

Alternative Names: ADS-5101; ADS-5102; amantadine ER; amantadine HCl; amantadine HCl extended release; GOCOVRI; Nurelin

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adamas Pharmaceuticals
  • Class Adamantanes; Antiparkinsonians; Antivirals; Organic bridged compounds; Small molecules
  • Mechanism of Action Dopamine receptor agonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Drug-induced dyskinesia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Drug-induced dyskinesia
  • Phase III Movement disorders
  • Discontinued Brain injuries

Most Recent Events

  • 22 Jun 2018 Efficacy data from a pooled analysis from the phase III EASE LID and EASE LID 3 trials in Drug-induced dyskinesia reported released by Adamas Pharmaceuticals
  • 24 May 2018 Pharmacokinetics data from three trials in Drug-induced dyskinesia released by Adamas
  • 19 Apr 2018 Adamas completes the phase III EASE LID 2 trial in Drug-induced dyskinesia in US, Austria, Canada, France, Germany and Spain (NCT02202551) (EudraCT2014-003739-20)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top